Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Quotes

Analysis

Analyst Ratings

News

Press Releases

Twitter

Media Mentions

Ownership

Earnings

Ampio Pharmaceuticals, Inc. (AMPE) 5.15 0.03
Price Open:5.01Day's Range:0.00000 - 5.55000
Price Close:5.0052wk Range:0.00000 - 8.50
Price Day Change:0.03Volume:114,984
Price % Change:0.60Market Cap:186.6M
Bid:4.56000PE Ratio:0
Ask:5.15000EPS Diluted:-0.365
Trade AMPE NOW!

The Latest On AMPE

Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee 4/25/13 8:02am
A Peek Into The Market Before The Trading Starts 4/2/13 7:09am
Ampio Receives FDA Acceptance for Clinical Trial of Ampion for Treatment of Osteoarthritis of the Knee 4/2/13 6:05am
Benzinga's Small Cap Movers for Monday March 11, 2013 3/11/13 6:33pm
UPDATE: Aegis Capital Reiterates Buy Rating, Raises PT on Ampio Pharmaceuticals on Clinical Milestones 3/4/13 9:09am
Ampio Pharmaceuticals Begins Clinical Trial of Optina for Diabetic Macular Edema 2/27/13 6:54am
A Peek Into The Market Before The Trading Starts 2/25/13 8:13am
Ampio Pharmaceuticals Announces Phase 3 Ampion Study for Osteoarthritis of the Knee to Include a Dose-Escalation Run-in Study 2/25/13 6:56am
A Peek Into The Market Before The Trading Starts 1/22/13 8:15am
FDA Accepts Ampio Pharmaceuticals IND for Optina for Treatment of Diabetic Macular Edema 1/22/13 6:50am
Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China 7/16/12 7:29am
From Earlier: Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,6M Shares at $3.25 7/13/12 7:43am
more
Press Releases
Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference 5/13/13 Newswire
Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee 4/25/13 Newswire
Ampio Receives FDA Clearance to Initiate Clinical Trial of Ampion™ for the Treatment of Osteoarthritis of the Knee: Patient Treatments have begun. 4/2/13 Newswire
Ampio Receives FDA Acceptance of its Patient Outcome for Premature Ejaculation (POPE) Questionnaire, Paving the Way for its US Pivotal Trial on Zertane™ 3/11/13 Newswire
Ampio Pharmaceuticals Initiates Clinical Trial of Optina™ in Diabetic Macular Edema (DME): First Patient Dosed 2/27/13 Newswire
Ampio Pharmaceuticals Modifies Ampion™ IND for Osteoarthritis of the Knee to Include A Dose Escalation Run-In Study and Prepares to Launch Pivotal Clinical Trial 2/25/13 Newswire
Ampio forms Luoxis Diagnostics to Commercialize ORP Technology 2/11/13 Newswire
Ampio Pharmaceuticals Announces Active IND for Optina™ for the Treatment of Diabetic Macular Edema (DME) 1/22/13 Newswire
Ampio Pharmaceuticals Announces Participation at Upcoming Investor Conference 1/22/13 Newswire

Get the latest AMPE stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Ampio Pharmaceuticals, Inc. stock price.

Partner Headlines
Stocks Maintain Early Lead; Drugmakers Alexion, Regeneron Climb 4/2/13
Health Care Sector Wrap 8/28/12
Coinstar, Supervalu Among Stocks Down on Above-average Volume Friday 7/13/12
Lexmark International, Ampio Pharmaceuticals Gapping Down Friday 7/13/12
Health Care Sector Wrap 7/12/12
Amylin Pharmaceuticals, Best Buy Among Stocks Up on High Volume Monday 7/2/12
Ampio Pharmaceuticals, Corinthian Colleges Among Stocks Gapping Up Monday 7/2/12
Company News for June 12, 2012 - Corporate Summary 6/12/12
Ampio Shares Rise Sharply 6/11/12
Health Care Sector Wrap 5/30/12
3 Strong Health Care Stocks Pros Love 9/23/11
6 Stocks Under $10 Moving Higher